Kenvue Inc. (NYSE:KVUE) to Issue Quarterly Dividend of $0.21

Kenvue Inc. (NYSE:KVUE) announced a quarterly dividend on Thursday, October 17th, RTT News reports. Shareholders of record on Wednesday, November 13th will be paid a dividend of 0.205 per share on Wednesday, November 27th. This represents a $0.82 annualized dividend and a yield of 3.82%. The ex-dividend date of this dividend is Wednesday, November 13th.

Kenvue has a dividend payout ratio of 67.2% meaning its dividend is sufficiently covered by earnings. Equities analysts expect Kenvue to earn $1.23 per share next year, which means the company should continue to be able to cover its $0.82 annual dividend with an expected future payout ratio of 66.7%.

Kenvue Price Performance

Shares of NYSE:KVUE opened at $21.46 on Friday. The company’s fifty day moving average price is $22.25 and its 200-day moving average price is $20.20. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.99 and a quick ratio of 0.68. The firm has a market capitalization of $41.08 billion, a price-to-earnings ratio of 27.51, a PEG ratio of 2.76 and a beta of 1.40. Kenvue has a one year low of $17.67 and a one year high of $23.55.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.28 by $0.04. The firm had revenue of $4 billion during the quarter, compared to analyst estimates of $3.93 billion. Kenvue had a return on equity of 21.80% and a net margin of 7.23%. The company’s revenue was down .3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.32 earnings per share. On average, equities research analysts anticipate that Kenvue will post 1.08 earnings per share for the current fiscal year.

Analyst Ratings Changes

KVUE has been the subject of several analyst reports. UBS Group upped their price target on shares of Kenvue from $20.00 to $22.00 and gave the company a “neutral” rating in a research report on Wednesday, August 7th. Jefferies Financial Group started coverage on Kenvue in a research report on Tuesday, September 24th. They set a “buy” rating and a $27.00 price target on the stock. Royal Bank of Canada downgraded Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 price objective for the company. in a research report on Tuesday, September 24th. Citigroup cut their target price on shares of Kenvue from $21.00 to $20.00 and set a “neutral” rating on the stock in a report on Wednesday, July 10th. Finally, Piper Sandler increased their price target on shares of Kenvue from $20.00 to $21.00 and gave the company a “neutral” rating in a research report on Monday, September 23rd. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, Kenvue currently has an average rating of “Hold” and an average price target of $22.20.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.